Booth BP - Search Results

1

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.

Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, Blumenthal GM, Turner DC, Li C, Ahamadi M, de Greef R, Chatterjee M, Kondic AG, Stone JA, Booth BP, Keegan P, Rahman A, Wang Y. Li H, et al. Among authors: booth bp. J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):403-414. doi: 10.1007/s10928-017-9528-y. Epub 2017 Jun 1. J Pharmacokinet Pharmacodyn. 2017. PMID: 28573468

2

Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.

Liu C, Yu J, Li H, Liu J, Xu Y, Song P, Liu Q, Zhao H, Xu J, Maher VE, Booth BP, Kim G, Rahman A, Wang Y. Liu C, et al. Among authors: booth bp. Clin Pharmacol Ther. 2017 May;101(5):657-666. doi: 10.1002/cpt.656. Epub 2017 Mar 22. Clin Pharmacol Ther. 2017. PMID: 28182273

3

The combination of exposure-response and case-control analyses in regulatory decision making.

Yang J, Zhao H, Garnett C, Rahman A, Gobburu JV, Pierce W, Schechter G, Summers J, Keegan P, Booth B, Wang Y. Yang J, et al. J Clin Pharmacol. 2013 Feb;53(2):160-6. doi: 10.1177/0091270012445206. Epub 2013 Jan 24. J Clin Pharmacol. 2013. PMID: 23436261 Clinical Trial.

4

Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug development.

Wang Y, Booth B, Rahman A, Kim G, Huang SM, Zineh I. Wang Y, et al. Clin Pharmacol Ther. 2017 May;101(5):582-584. doi: 10.1002/cpt.628. Epub 2017 Mar 15. Clin Pharmacol Ther. 2017. PMID: 28090657 Review.

5

Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective.

Bi Y, Liu J, Furmanski B, Zhao H, Yu J, Osgood C, Ward A, Keegan P, Booth BP, Rahman A, Wang Y. Bi Y, et al. Among authors: booth bp. Ann Oncol. 2019 Apr 1;30(4):644-651. doi: 10.1093/annonc/mdz037. Ann Oncol. 2019. PMID: 30715147 Free article.

6

Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.

Wang J, Song P, Schrieber S, Liu Q, Xu Q, Blumenthal G, Amiri Kordestani L, Cortazar P, Ibrahim A, Justice R, Wang Y, Tang S, Booth B, Mehrotra N, Rahman A. Wang J, et al. Clin Pharmacol Ther. 2014 May;95(5):558-64. doi: 10.1038/clpt.2014.24. Epub 2014 Jan 31. Clin Pharmacol Ther. 2014. PMID: 24488143 Clinical Trial.

7

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.

Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV. Ramchandani RP, et al. Among authors: booth bp. J Clin Pharmacol. 2007 Jan;47(1):78-86. doi: 10.1177/0091270006295060. J Clin Pharmacol. 2007. PMID: 17192505

8

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development.

Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, Gobburu J. Wang Y, et al. Among authors: booth bp. Clin Pharmacol Ther. 2009 Aug;86(2):167-74. doi: 10.1038/clpt.2009.64. Epub 2009 May 13. Clin Pharmacol Ther. 2009. PMID: 19440187

9

Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.

Grillo JA, Zhao P, Bullock J, Booth BP, Lu M, Robie-Suh K, Berglund EG, Pang KS, Rahman A, Zhang L, Lesko LJ, Huang SM. Grillo JA, et al. Among authors: booth bp. Biopharm Drug Dispos. 2012 Mar;33(2):99-110. doi: 10.1002/bdd.1771. Epub 2012 Mar 4. Biopharm Drug Dispos. 2012. PMID: 22270945

10

Pemetrexed in malignant pleural mesothelioma.

Hazarika M, White RM Jr, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R. Hazarika M, et al. Among authors: booth bp. Clin Cancer Res. 2005 Feb 1;11(3):982-92. Clin Cancer Res. 2005. PMID: 15709163

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page